Droc Ionel, Raithel Dieter, Calinescu Francisca B
Army's Center for Cardiovascular Diseases, Bucharest, Romania.
Minim Invasive Ther Allied Technol. 2011 Apr;20(2):117-24. doi: 10.3109/13645706.2011.554842.
Endovascular aneurysm repair (EVAR) is an attractive alternative to open surgical approach in treating abdominal aortic aneurysms (AAA). In Nuerenberg in our 14-year experience of 1502 cases (ending December 2007) we used 13 different endografts. The median follow-up was 41 months (1.0-98) and the AAA had a mean diameter of 52.4 mm. Five-hundred and nineteen cases were done using Powerlink grafts. The 30 day mortality was 1.7%. The total reintervention rate was 5.3%, while no distal migration, conversion or post EVAR rupture occurred. At the Army's Center for Cardiovascular Diseases, Bucharest, between July 2008 and December 2009, 15 patients underwent EVAR for AAA. We used the following types of endografts: one Anaconda, three Medtronic Talent, seven Endologix Powerlink and four EVITA Jotec. The mean hospitalization time was three days. Follow-up was done by CT-scan at one, three, six, and 12 months. No endoleaks or infection were seen in the short and medium term follow-up. EVAR is an appropriate treatment for selected patients, especially those at high risk for open surgical repair. The future of EVAR as the potential gold standard for aortic aneurysm therapy rests upon the vision and creativity of both surgeons and technology innovators to realize the potential of endovascular interventions.
血管内动脉瘤修复术（EVAR）是治疗腹主动脉瘤（AAA）时替代开放手术方法的一种有吸引力的选择。在纽伦堡，根据我们14年里1502例病例（截至2007年12月）的经验，我们使用了13种不同的血管内移植物。中位随访时间为41个月（1.0 - 98个月），腹主动脉瘤的平均直径为52.4毫米。519例手术使用了Powerlink移植物。30天死亡率为1.7%。总再次干预率为5.3%，同时未发生远端移位、中转或血管内动脉瘤修复术后破裂。在布加勒斯特的陆军心血管疾病中心，2008年7月至2009年12月期间，15例患者接受了腹主动脉瘤的血管内动脉瘤修复术。我们使用了以下类型的血管内移植物：1例使用Anaconda，3例使用美敦力Talent，7例使用Endologix Powerlink，4例使用EVITA Jotec。平均住院时间为3天。在1、3、6和12个月时通过CT扫描进行随访。在短期和中期随访中未发现内漏或感染。血管内动脉瘤修复术是适合特定患者的治疗方法，尤其是那些开放手术修复风险高的患者。血管内动脉瘤修复术作为主动脉瘤治疗潜在金标准的未来取决于外科医生和技术创新者的远见和创造力，以实现血管内干预的潜力。
